Memorial Sloan Kettering Cancer Center
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1884-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.mskcc.org
Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer
Phase 1
Completed
- Conditions
- Lung Cancer
- First Posted Date
- 2004-07-19
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00005806
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer
Phase 1
Completed
- Conditions
- Prostate Cancer
- Interventions
- Biological: MUC1-KLH vaccine/QS21
- First Posted Date
- 2004-07-19
- Last Posted Date
- 2013-01-31
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT00005632
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome
Phase 2
Completed
- Conditions
- LymphomaMyelodysplastic SyndromesMultiple Myeloma and Plasma Cell NeoplasmLeukemia
- First Posted Date
- 2004-07-19
- Last Posted Date
- 2013-06-27
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00002502
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
T138067 Sodium in Treating Patients With Advanced Refractory Cancer
Phase 1
Completed
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2004-07-16
- Last Posted Date
- 2013-06-25
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT00003359
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Irinotecan and Flavopiridol in Treating Patients With Advanced Liver Cancer
Phase 2
Completed
- Conditions
- Liver Cancer
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00087282
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation
Phase 1
Terminated
- Conditions
- LeukemiaLymphomaLymphoproliferative Disorder
- Interventions
- Biological: beta-glucanBiological: rituximab
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2013-03-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT00087009
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Ifosfamide and Topotecan in Treating Patients With Refractory Solid Tumors
Phase 1
Completed
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2004-07-08
- Last Posted Date
- 2013-06-27
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00003198
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Combination Chemotherapy in Treating Pediatric Patients With Stage III or IV Non-Hodgkin's Lymphoma
Phase 2
Completed
- Conditions
- Lymphoma
- First Posted Date
- 2004-07-01
- Last Posted Date
- 2013-06-25
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00002691
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer
Phase 1
Completed
- Conditions
- Ovarian CancerPrimary Peritoneal Cavity CancerFallopian Tube Cancer
- First Posted Date
- 2004-06-28
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00006041
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Combination Chemotherapy and Biological Therapy in Treating Patients With High-Risk Ewing's Sarcoma
Phase 2
Completed
- Conditions
- Sarcoma
- First Posted Date
- 2004-06-24
- Last Posted Date
- 2013-06-25
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00003667
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
© Copyright 2025. All Rights Reserved by MedPath